SEC Form 4 · accession 0001628280-26-061444
Arcutis Biotherapeutics, Inc. · ARQT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Masaru Matsuda
Officer — See Remarks
Period of report
Sep 8, 2026
Accepted (ET)
Sep 10, 2026 · 7:24 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001787306
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Sep 8, 2026 | S | 9,989 | $25.0261 | D | 116,182 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The transactions reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on June 5, 2026, by the Reporting Person, with a plan end date of September 1, 2027.
- F2The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.12, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Remarks
Reporting Person's title: EVP, Chief Legal Officer